SuperworthBiodesix EPS BDSX
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$3.17
- Latest quarter, Q2 FY26
- −$0.71
- Fiscal year 2025
- −$4.73
Biodesix's earnings per share was −$3.17 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.71.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.73 | n/a |
| FY2024 | −$6.93 | n/a |
| FY2023 | −$13.00 | n/a |
| FY2022 | −$31.80 | n/a |
| FY2021 | −$31.40 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.71 | n/a | −$3.17 | |
| Q1 FY26 | −$0.81 | n/a | −$4.02 | |
| Q4 FY25 | −$0.49 | n/a | −$4.73 | |
| Q3 FY25 | −$1.16 | n/a | −$5.37 | |
| Q2 FY25 | −$1.56 | n/a | −$5.61 | |
| Q1 FY25 | −$1.52 | n/a | −$5.65 | |
| Q4 FY24 | −$1.13 | n/a | −$6.93 | |
| Q3 FY24 | −$1.40 | n/a | −$7.80 | |
| Q2 FY24 | −$1.60 | n/a | −$9.20 | |
| Q1 FY24 | −$2.80 | n/a | −$11.00 | |
| Q4 FY23 | −$2.00 | n/a | −$13.00 | |
| Q3 FY23 | −$2.80 | n/a | −$18.00 |
Against its peers
Companies in Healthcare nearest Biodesix's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BDSXBiodesix | −$3.17 | |
| ELMDElectromed | $1.31 | +56% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| VMDViemed Healthcare | $0.36 | +6% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| ARVNArvinas | $0.16 | |
| NRCNRC Health | $0.25 | −67% a year |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Biodesix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.